IL31 Canine, HEK
HEK293 Cells.
IL-31, Interleukin 31, IL31.
Greater than 90.0% as determined by SDS-PAGE.
Description
IL31 Canine Recombinant is a single, glycosylated, polypeptide chain (24-159 a.a) containing a total of 136 amino acids, having a molecular mass of 25.2 kDa. IL31 is purified by proprietary chromatographic techniques.
Product Specs
Recombinant Canine IL31 is a single, glycosylated polypeptide chain encompassing amino acids 24-159, totaling 136 amino acids. It possesses a molecular mass of 25.2 kDa. This IL31 protein has been purified using proprietary chromatographic techniques.
The IL31 solution is provided at a concentration of 1 mg/ml. It is formulated in a buffer containing 10% glycerol and Phosphate-Buffered Saline (pH 7.4).
Purity exceeds 90.0% as determined by SDS-PAGE analysis.
IL-31, Interleukin 31, IL31.
HEK293 Cells.
SHMAPTHQLP PSDVRKIILE LQPLSRGLLE DYQKKETGVP ESNRTLLLCL TSDSQPPRLN SSAILPYFRA IRPLSDKNII DKIIEQLDKL KFQHEPETEI SVPADTFECK SFILTILQQF SACLESVFKS LNSGPQ.
Product Science Overview
Interleukin-31 (IL-31) is a cytokine that has garnered significant attention due to its involvement in various inflammatory processes and immune responses. Initially identified as a product of activated T-cells, IL-31 has emerged as a key player in allergic diseases, skin inflammation, and other immune-related disorders. The recombinant form of IL-31, specifically Interleukin-31 Canine Recombinant, produced in Human Embryonic Kidney (HEK) cells, is a valuable tool for research and therapeutic applications.
Interleukin-31 Canine Recombinant, HEK, is a single, glycosylated polypeptide chain consisting of 136 amino acids, with a molecular mass of approximately 25.2 kDa . The recombinant protein is produced in HEK293 cells, which are known for their high efficiency in protein expression and post-translational modifications. The protein is purified using proprietary chromatographic techniques to ensure high purity and functionality .
IL-31 exerts its effects through binding to the IL-31 receptor, which is predominantly expressed on various immune cells, including T-cells, mast cells, and dendritic cells . Upon receptor activation, IL-31 triggers a cascade of intracellular signaling events, leading to the release of pro-inflammatory mediators, modulation of cell differentiation, and induction of pruritus (itching). Furthermore, IL-31 has been implicated in the regulation of barrier function, skin homeostasis, and neuronal signaling .
IL-31 signaling involves the activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways . This leads to the phosphorylation of downstream effectors and the subsequent modulation of gene expression. The activation of these pathways results in the production of various cytokines and chemokines that contribute to the inflammatory response .
The recombinant form of IL-31 is widely used in research to study its role in immune regulation and disease pathogenesis. It is particularly valuable in investigating allergic skin disorders, such as atopic dermatitis, where IL-31 is known to play a crucial role . Additionally, IL-31 is being explored as a potential therapeutic target for various inflammatory and autoimmune diseases .
